about
Suggested guidelines for the diagnosis and management of urea cycle disordersHemophilia A: an ideal disease to correct in uteroNew Strategies for the Treatment of Phenylketonuria (PKU)Analysis of biodistribution and engraftment into the liver of genetically modified mesenchymal stromal cells derived from adipose tissueStable H3 peptide was delivered by gold nanorods to inhibit LSD1 activation and induce human mesenchymal stem cells differentiationModeling inherited metabolic disorders of the liver using human induced pluripotent stem cells.Bone marrow stem cells and liver regenerationFrom skin cells to hepatocytes: advances in application of iPS cell technologyTherapeutic potential of transplanted placental mesenchymal stem cells in treating Chinese miniature pigs with acute liver failure.Mesenchymal stem cells as therapeutics and vehicles for gene and drug deliveryTransplantation of ATP7B-transduced bone marrow mesenchymal stem cells decreases copper overload in rats.Embryonic hepatocyte transplantation for hepatic cirrhosis: efficacy and mechanism of action.Treatment of Hemophilia A in Utero and Postnatally using Sheep as a Model for Cell and Gene DeliveryThe hematopoietic system in the context of regenerative medicine.Embryonic and induced pluripotent stem cells as a model for liver disease.Cryopreserved hepatic progenitor cells derived from human embryonic stem cells can arrest progression of liver fibrosis in rats.Incorporation of VSV-G produces fusogenic plasma membrane vesicles capable of efficient transfer of bioactive macromolecules and mitochondria.Labeling of primary human hepatocytes with micron-sized iron oxide particles in suspension culture suitable for large-scale preparation.Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells.Human mesenchymal stem cell-engineered hepatic cell sheets accelerate liver regeneration in mice.Effect of bone marrow mesenchymal stem cell transplantation on acute hepatic failure in rats.Rodent animal models for surrogate analysis of cell therapy in acute liver failureEfficient Differentiation of Human Induced Pluripotent Stem Cell (hiPSC) Derived Hepatocyte-Like Cells on hMSCs Feeder.External inosculation as a feature of revascularization occurs after free transplantation of murine liver grafts.Human-induced pluripotent stem cells as a source of hepatocyte-like cells: new kids on the block.Human heterologous liver cells transiently improve hyperammonemia and ureagenesis in individuals with severe urea cycle disorders.Alternative Cell Sources to Adult Hepatocytes for Hepatic Cell Therapy.Decellularization and Solubilization of Porcine Liver for Use as a Substrate for Porcine Hepatocyte Culture: Method Optimization and Comparison.Notch is the key factor in the process of fetal liver stem/progenitor cells differentiation into hepatocytes.Long-term outcome following pediatric liver transplantation for metabolic disorders.Blockade of endothelial G(i) protein enhances early engraftment in intraportal cell transplant to mouse liver.Clinical Outcome of Hepatocyte Transplantation in Four Pediatric Patients with Inherited Metabolic Diseases
P2860
Q21202856-B30DC5D1-4491-4843-B51C-94F761DCC572Q26852638-3781C187-31D3-41A9-8B50-509C5B709846Q26999278-86939C89-A439-4973-B538-7F5E3A99755AQ28263447-A30BC397-B4B9-4EFC-AEFC-5888040BE902Q33618587-42C26CA0-1D74-4A27-B56B-FEA7D9D75677Q33672762-6F29D1BA-D5CF-4C6E-8D4F-225EADC167F4Q33903059-93286672-3A75-454F-9D23-F054FE28702AQ34090265-310752F4-C2C3-4BB1-86A0-1D56A0AE5BECQ34294896-FE0077C5-9568-4B42-9CC5-BE15D4D5DF67Q34349428-69D5240F-8F92-43C0-92A6-F71BF9591B08Q35399294-3D704846-B39E-4720-A6AE-DA112C941543Q35681501-B412179C-DED5-49BD-A67C-6253A01D9DD2Q36477364-11426F21-2EB2-4711-AAEB-9A3F0B6128B9Q36627127-9F9E6CF2-319D-40C5-A95C-545D4309F8BDQ36980068-F23A656A-B7ED-479E-8C15-975C716BE9E8Q38756104-91E02228-CF59-48B1-A657-C8251319EB05Q38771915-9AC12923-5AC7-4360-A8FE-D5067B077204Q39775421-B948BBBE-3BE1-4DCE-8BC0-4B08D9F5902EQ39802426-60A079D5-05E2-4C6E-B349-3765D1768C68Q41136479-6F3E7A26-02AB-4017-A510-A23C8BE2A13FQ41754256-C4108880-0038-4BEB-8691-AF46488DA6A7Q42556938-D6F8B6C0-C4DA-41B1-94E8-90C5559ABD0FQ43168906-207E5E3E-2573-437D-99D3-AAF59805623BQ44738565-FF5B90EE-C931-4064-84AA-00D8DEF94A9FQ45308555-84CDB8D0-E58A-4E64-BC6A-2F9E78A58A6FQ48194077-975BF799-3E92-45D7-BCC6-85A63AD99528Q48661191-8347A1E9-16D7-4C09-ADCE-20DC7197CE7BQ49484206-07E1530B-90CD-49D3-82F8-913C39CF7EA3Q50802855-7FC3A650-D201-44EC-B81F-BAB011DC0B58Q51864807-0957CEBA-9D5C-4250-BF12-924F71413120Q52624562-66C60A9D-2AF6-4AEC-B9FA-9766E1FED922Q58680778-BD4ED74E-82BD-4F19-A8F7-EB57469ED0C9
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cell-based therapies for metabolic liver disease.
@en
Cell-based therapies for metabolic liver disease.
@nl
type
label
Cell-based therapies for metabolic liver disease.
@en
Cell-based therapies for metabolic liver disease.
@nl
prefLabel
Cell-based therapies for metabolic liver disease.
@en
Cell-based therapies for metabolic liver disease.
@nl
P1476
Cell-based therapies for metabolic liver disease.
@en
P2093
Gregory M Enns
Maria T Millan
P356
10.1016/J.YMGME.2008.06.001
P577
2008-07-18T00:00:00Z